Why Arcturus Therapeutics Stock Was Up 16% Thursday
Arcturus Therapeutics (NASDAQ: ARCT), which focuses on clinical-stage messenger RNA (mRNA) medicines, saw its shares rise 16% on Thursday. The stock closed at $35.52 on Wednesday, then opened at $38 today and rose to as high as $41.15 by midmorning. The stock has a 52-week high of $124 and a low of $24.87, and is down more than 7% so far this year.
Image source: Getty Images.
The biotech company gave an update about studies of ARCT-154 and ARCT-165, two of its mRNA COVID vaccine candidates, that it is evaluating as a primary vaccine and as a booster for the Comirnaty vaccine produced by Pfizer and BioNTech. The preliminary results showed that the first 8 of 12 participants in the ARCT-154 study and the first 9 of 12 participants in the ARCT-165 study had increased antibodies to fight COVID and neutralization against various COVID variants, including the alpha, beta, gamma, and delta strains.
Source Fool.com
